Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer.

Autor:	Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: tyoshino@east.ncc.go.jp., Argilés G; Luis Diaz Laboratory, MSKCC, Sloan Kettering Institute, New York, USA., Oki E; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Martinelli E; Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy., Taniguchi H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Arnold D; Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany., Mishima S; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Li Y; Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China., Smruti BK; Department of Medical Oncology, Lilavati Hospital and Research Centre and Bombay Hospital, Mumbai, India., Ahn JB; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Seoul, Korea., Faud I; Department of Radiotherapy & Oncology, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia., Chee CE; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Yeh KH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Lin PC; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Chua C; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore., Hasbullah HH; Oncology Unit, Faculty of Medicine, UiTM Sg Buloh, Selangor, Malaysia., Lee MA; Division of Medical Oncology, Department of Internal Medicine, Cancer Research Institute, College of Medicine, St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea., Sharma A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India., Sun Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Curigliano G; Istituto Europeo di Oncologia, IRCCS and University of Milano, Milan, Italy., Bando H; Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan., Lordick F; Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Diseases, University Cancer Center, Leipzig University Medical Center, Leipzig, Germany., Yamanaka T; Department of Biostatistics, Yokohama City University, Kanagawa, Japan., Tabernero J; Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain., Baba E; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Cervantes A; CIBERONC, Department of Medical Oncology, Institute of Health Research, INCLIVIA, University of Valencia, Valencia, Spain., Ohtsu A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Peters S; Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Ishioka C; Department of Clinical Oncology, Tohoku University School of Medicine, Sendai, Japan., Pentheroudakis G; ESMO, Lugano, Switzerland.
Jazyk:	angličtina
Zdroj:	Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Dec; Vol. 32 (12), pp. 1496-1510. Date of Electronic Publication: 2021 Aug 16.
DOI:	10.1016/j.annonc.2021.08.1752
Abstrakt:	The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (ISMPO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug availability and reimbursement situations in the different Asian countries. Competing Interests: Disclosure TY has reported research funding from Taiho Pharmaceuticals, Sumitomo Dainippon Pharma Co., Ltd, Chugai Pharmaceutical Co., Ltd, Sanofi KK, Daiichi Sankyo Co., Ltd, Parexel International Inc. and ONO Pharmaceutical Co., Ltd. GA has reported that he has acted as a consultant or speaker for Amgen, Roche, Merck, Sanofi, Servier, Merck Sharp & Dohme and Bayer. EO has declared fees for consultancy, speaking and advisory roles from Eli Lilly, Taiho Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., Takeda, Pharmaceuticals, ONO Pharmaceutical Co., Ltd., Bayer and Bristol-Myers Squibb. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, AstraZeneca, Bayer, Merck Serono, Pierre Fabre, Incyte and Sanofi and speaker support from ESMO. HT declares research funding from RDKK, Sysmex, Daiichi Sankyo, Taiho and Takeda. DA has acted as a consultant or speaker for ACE Oncology, Amgen, Aptitude Health, art tempi media, AstraZeneca, Bayer, Boston Scientific, Bristol-Myers Squibb, CCO, CRA International, Eli Lilly, From Research to Practice, Hexal, Imedex, Ipsen, IQIVIA, Ketchum, MedAhead (Austria), Merck Serono, Merck Sharp and Dohme, Oncolytics, PharmaCept, Pierre Fabre, PRIMA Consulting, Roche, Samsung Bioepsis, Sanofi (Genyme), Terumo and Servier; received fees from Elsevier, WebHealth and Oxford University Press; and institutional funding from Bristol-Myers Squibb, OncoLytics and Pierre Fabre. BKS declares fees for consultancy and advisory roles from Eli Lilly, Novartis, Pfizer, AstraZeneca and Boehringer Ingelheim. IF declares fees for consultancy and advisory roles from Roche, AstraZeneca, Pfizer Merck and Novartis and research funding from Genetech, Samsung and Boehringer Ingelheim. K-HY declares fees for consultancy and advisory roles from Amgen, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Merck Serono, Eli Lilly, ONO Pharmaceuticals, Takeda, Merck Sharp and Dohme, Daiichi Sankyo and AstraZeneca. GC declares fees for consultancy and advisory roles from AstraZeneca, Daichii Sankyo, Bristol-Myers Squibb, Lilly, Pfizer, Novartis, Ellipsis, Merck and Seagen. HB declares fees for consultancy and advisory roles from Eli Lilly, Taiho Pharmaceuticals and ONO Pharmaceutical Co., Ltd. FL declares fees for consultancy, speaking and advisory roles from Amgen, Astellas, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Eli Lilly, Imedex, MedUpdate, Merck Serono, Merck Sharp and Dohme, Promedicis, Roche, Servier, StreamedUp and Zymeworks; writing fees from Deutscher Arzteverleg, Imedico and Springer-Nature; expert testimony fees from Biontech and Elsevier; and research funding from Bristol-Myers Squibb. TY declares research funding from Chugai, Bayer and Taiho. JT reports personal financial interest in the form of scientific consultancy roles for Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, Merck Sharp and Dohme, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics and TheraMyc; and educational collaborations with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). EB declares research funding from Bristol-Myers Squibb, Merck Sharp & Dohme, Eisai, Taiho, Bayer, Eli Lilly and Daichi-Sankyo. AC has reported fees for consultancy and advisory roles from Merck Serono, Amgen, BeiGene and Bristol-Myers Squibb; and research funding from AbbVie, Actuate Therapeutics, Alkermes Inc, Amgen, Astellas Pharma, Beigene, Bioncotech Therapeutics, Boehringer Ingelheim, Debiopharm International, F. Hoffmann-La Roche, FibroGen, Genmab, Janssen Research & Development, MedImmune, Meranini Ricerche, Novartis, Puma Biotechnology, Symphogen, Tahio, Transgene and WNT Research. AO has received research funding from Bristol-Myers Squibb. SP has reported fees for consultancy/advisory roles from AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, Foundation Medicine, Illumina, Imedex, Incyte, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, Roche/Genentech, RTP, Sanofi, Seattle Genetics and Takeda; speaker roles for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi and Takeda; and the receipt of grants/research support: (sub)investigator in trials (institutional financial support for trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, Pfizer, Phosplatin Therapeutics and Roche/Genentech. CI has received research funding from Chugai, Taiho, Daiichi-Sankyo, Takeda, Shionogi, Novartis, Eisai, Sanofi, Yakult, Merck Serono, Ono, Kyowa-Kirin, Nippon-Kayaku and Eli Lilly. GP reports fees for consultancy/advisory roles from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Merck Sharp and Dohme and Roche; and institutional funding from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Debiopharm, Enorasis, Genekor, Ipsen, Janssen, Lilly, Merck, Merck Sharp and Dohme, Pfizer, Roche, Sanofi and Servier. The remaining authors have declared no conflicts of interest (Copyright © 2021. Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu